Evaluation of Budesonide–Hydroxypropyl-β-Cyclodextrin Inclusion Complex in Thermoreversible Gels for Ulcerative Colitis

[1]  D. D. de Araújo,et al.  Pharmacokinetics and Pharmacodynamics Evaluation of Tramadol in Thermoreversible Gels , 2017, BioMed research international.

[2]  A. T. Te Velde,et al.  Actual Usage and Quality of Experimental Colitis Models in Preclinical Efficacy Testing: A Scoping Review , 2016, Inflammatory bowel diseases.

[3]  A. Rengarajan,et al.  Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach , 2016, Clinical and experimental gastroenterology.

[4]  H. Vogelsang,et al.  Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults. , 2016, World journal of gastrointestinal pharmacology and therapeutics.

[5]  Alessandra Cristina Santos Akkari,et al.  Budesonide-hydroxypropyl-β-cyclodextrin inclusion complex in binary poloxamer 407/403 system for ulcerative colitis treatment: A physico-chemical study from micelles to hydrogels. , 2016, Colloids and surfaces. B, Biointerfaces.

[6]  Nidhi,et al.  Microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: A brief review , 2014, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[7]  G. Lichtenstein.  Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis , 2015, Digestive Diseases and Sciences.

[8]  L. Klouda.  Thermoresponsive hydrogels in biomedical applications: A seven-year update. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[9]  Q. Pittman,et al.  Toward a better understanding of the central consequences of intestinal inflammation , 2015, Annals of the New York Academy of Sciences.

[10]  Nirmal Singh,et al.  A Review on Chemical-Induced Inflammatory Bowel Disease Models in Rodents , 2014, The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology.

[11]  A. Gambero,et al.  Hepcidin expression in colon during trinitrobenzene sulfonic acid-induced colitis in rats. , 2014, World journal of gastroenterology.

[12]  M. Iborra,et al.  Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis , 2014, Clinical and experimental gastroenterology.

[13]  G. Rogler,et al.  Topical therapy is underused in patients with ulcerative colitis. , 2014, Journal of Crohn's & colitis.

[14]  Jian Fei,et al.  Bioluminescence imaging for IL-1β expression in experimental colitis , 2013, Journal of Inflammation.

[15]  Burkhard Becher,et al.  IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4+ Th17 cells , 2012, The Journal of experimental medicine.

[16]  C. Hiruma-Lima,et al.  Suppression of TNBS-induced colitis in rats by 4-methylesculetin, a natural coumarin: comparison with prednisolone and sulphasalazine. , 2012, Chemico-biological interactions.

[17]  J. Stein,et al.  Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left‐sided ulcerative colitis , 2010, Alimentary pharmacology & therapeutics.

[18]  A. Gambero,et al.  Attenuation of colitis injury in rats using Garcinia cambogia extract , 2009, Phytotherapy research : PTR.

[19]  I. Mikšík,et al.  Glucocorticoid Availability in Colonic Inflammation of Rat , 2008, Digestive Diseases and Sciences.

[20]  H. Eichler,et al.  Colonic spread and serum pharmacokinetics of budesonide foam in patients with mildly to moderately active ulcerative colitis , 2005, Alimentary pharmacology & therapeutics.

[21]  R. Modigliani,et al.  Comparison of budesonide and 5‐aminosalicylic acid enemas in active distal ulcerative colitis , 1995, Alimentary pharmacology & therapeutics.